Evotec, a drug discoverer facing challenges under CEO Christian Wojczewski, confirmed receiving the unsolicited offer. The ...

Halozyme Therapeutics (NASDAQ:HALO) announced on Thursday its plans to acquire German drug developer Evotec SE ADR (NASDAQ:EVO) in a deal valued at approximately 2 billion euros ($2.10 billion), to ...

Halozyme intends to purchase all the shares of Evotec at 11 euros per share, which represents a premium of 27.5% to Evotec's last close price. U.S.-listed shares of Evotec were up 6.3%, while those of ...

German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics , Bloomberg News reported on Thursday.

Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other ...

FRANKFURT: Europe’s main stock index logged its best day in six weeks on Monday, with defence stocks in the lead ...

Europe’s shares rose on Monday, with defence stocks feeling the benefit amid hopes for higher spending in Europe under Donald ...

Germany-based Evotec SE (NASDAQ:EVO) is trading on Monday after a report that suggests the company is a takeover target. The ...

Evotec surged on Monday as it emerged that private equity firm Triton Partners is considering a takeover bid for the German drug development company after taking a near-10% stake.

Shares in Evotec jumped as much as 13.3% on Monday after regulatory filings showed private equity firm Triton had built an over 9% stake in the German drug development company.

Evotec listed three investors with stakes of 5% or greater in its 2023 annual report. At that time, T. Rowe Price was the ...